8 completed. 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 3 | Completed 3 |
Follow Hyponatremia: new trials by email Literature Review of Hyponatremia trials Research Report on Hyponatremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 17 | 2017-12-15 | 2021-12-13 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Empagliflozin, Placebo - SIADH | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 88 | 2016-09-05 | 2019-06-13 |
| Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 15 | 2016-03-01 | 2016-08-10 |
| Efficacy Study of VA106483 in Males With Nocturia. VA106483 - Nocturia | Phase 2 | Completed | Vantia Ltd | 152 | 2009-12-01 | 2014-06-20 |
| A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Tolvaptan, Placebo - Hypovolemic Hyponatremia | Phase 2 | Completed | Otsuka Beijing Research Institute | 241 | 2008-05-01 | 2025-03-25 |
| Hypertonic Saline Solution in Heart Failure NaCl 7,5% (Hypertonic Saline Solution), NaCl 0,9% - Heart Failure, Renal Failure | Phase 2 | Completed | University of Sao Paulo | 34 | 2008-02-01 | 2014-06-10 |
| Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites satavaptan (SR121463B) - Ascites, Liver Cirrhosis | Phase 2 | Completed | Sanofi | 110 | 2004-04-01 | 2009-01-12 |
| Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion satavaptan (SR121463B) - Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia | Phase 2 | Completed | Sanofi | 35 | 2001-06-01 | 2008-06-17 |
Inappropriate ADH Syndrome (4) · Ascites (1) · Heart Failure (1) · Liver Cirrhosis (1) · Nocturia (1) · Renal Insufficiency (1)
Metabolic Diseases (8) · Nutritional and Metabolic Diseases (8) · Water-Electrolyte Imbalance (8) · Brain Diseases (4) · Central Nervous System Diseases (4) · Endocrine System Diseases (4) · Hypothalamic Diseases (4) · Nervous System Diseases (4) · Pituitary Diseases (4) · Pathological Conditions, Signs and Symptoms (2) · Cardiovascular Diseases (1) · Digestive System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosis (1)
empagliflozin (3) · satavaptan (2) · Saline Solution, Hypertonic (1) · Tablets (1) · Tolvaptan (1)
University Hospital, Basel, Switzerland (3) · Sanofi (2) · Otsuka Beijing Research Institute (1) · University of Sao Paulo (1) · Vantia Ltd (1)
Switzerland (3) · Belgium (2) · France (2) · Germany (2) · Hungary (2) · United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Croatia (1) · Czechia (1) · Italy (1) · Romania (1)
Aris Nikas (1) · Bruce Rankin (1) · Chris Ng (1) · David Beccia (1) · Earl Martin (1) · Edimar A Bocchi, Professor (1) · Elizabeth Houser (1) · Evan Goldfischer (1) · Feng Gu (1) · H. David Mitcheson (1) · Howard Hezmall (1) · Jidong Jia (1) · Joseph Parkhurst (1) · Kenneth Blaze (1)
PMID 17992382, PMID 18508290, PMID 22243938, PMID 24906029, PMID 30180806, PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233
2015 (1), 2017 (1)